Clinical Trial Update: Rifaximin Modify the Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD)

View source ↗

Summary

This update reports the completed clinical trial NCT02884037 sponsored by Mansoura University, evaluating rifaximin for modifying the pathogenesis of non-alcoho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• Rifaximin (rifaximin)

Snippet

Sponsor: Mansoura University | Conditions: Non-alcoholic Fatty Liver Disease | Status: COMPLETED